Shareholder letter...
Shareholder letter...
GT Biopharma, Inc. (NASDAQ: GTBP) is a clinical stage immuno-oncology company focused on developing innovative therapies based on the Company's proprietary NK cell engager (TriKE®) technology. TriKE® therapeutic agents are targeted immunotherapeutic agents that simultaneously react with natural killer (NK) cells and cancer cells to selectively facilitate the killing of cancer cells.
GT Biopharma Reports Third Quarter 2024 Financial Results
Nov 14, 2024 • 4:00 EST | Read More
GT Biopharma to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference
Sep 26, 2024 • 9:15 EDT | Read More